Status and phase
Conditions
Treatments
About
The purpose of this study is to examine the efficacy of using Solum IV and bone marrow concentrate with general fluid concentrate in Transforaminal Lumbar Interbody Fusion (TLIF).
Full description
This is a prospective, single-center clinical study. Ten patients will be enrolled and undergo an TLIF with a spinal fixation system and receive Solum IV (Celling Biosciences) and patient's BMC with GFC.
The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
All study subjects will be assessed for fusion rate, complication rates and subject-reported outcomes at designated intervals up to 12 months after surgery. X-rays (anterior-posterior, lateral, flexion-extension) will be taken at pre-operatively, 3, 6, and 12 months post-treatment.
Sex
Ages
Volunteers
Inclusion criteria
Subject is skeletally mature and older than 18 years of age
One and contiguous 2 or 3 level primary lumbar fusions.
L1 to S1 with a primary diagnosis of one or more of the following:
Subject has received conservative (non -surgical treatment for back pain for a minimum of 6 months and is unresponsive
Subject understand the conditions of enrollment and is willing to sign and date the informed consent form
Subject agrees to comply with study visits
Exclusion criteria
Previous bilateral Iliac Crest Bone Graft (ICBG) harvest
Previous instrumented fusion at the same or adjacent level
Active systemic infection, infection localized to the site of implantation or at aspiration site
Vulnerable patients
Pregnant women or interested in becoming pregnant in the next 12 months
Subjects with certain autoimmune diseases (such as lupus)
Subject has progressive neuromuscular disease
Active hepatitis, AIDS, ARS or is HIV positive
Syringomyelia at any spinal levels
Any other condition that would interfere with the subject self-assessment of pain, function or quality of life
Subjects with multiple allergies
Subjects with any history of cancer (except for basal cell carcinoma of the skin)
Significant osteoporosis
Subject is younger than or equal to 18 years of age
Subjects with a BMI of 40 or greater
Subject has diabetes mellitus requiring daily insulin management
Subject has allergy to implant materials (such as titanium, titanium alloy)
Subject has primary or metastatic tumors involving the spine
Subject is participating in another investigational study for a similar purpose
Subject has a history of significant mental illness or mental incapacity
Subject is currently smoker and will not cease smoking from the time of study enrollment up through 3 months post-operatively, nicotine users for whom post-operative bone stimulation would be prescribed, or has a recent history of alcohol or other substance abuse within the past 2 years
Subject is receiving workers compensation
Absence of English language reading or writing skills
Primary purpose
Allocation
Interventional model
Masking
0 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal